DPH00X

DPH00X is a preclinical-stage drug candidate being developed by Disruptive Pharma (also known as DISruptive Oncology). The program utilizes the company's proprietary Pharma-Shell technology, which is based on mesoporous magnesium carbonate (MMC). This technology is designed to transform poorly soluble active pharmaceutical ingredients (APIs) into stable, amorphous forms, thereby significantly enhancing their solubility and oral bioavailability. While DPH00X is categorized within the company's oncology pipeline, the specific molecular target, mechanism of action, and primary cancer indication have not yet been disclosed (TBA). The '00X' designation suggests it may represent an early-stage or undisclosed project within the DPH series.